Comparison between 90‐degree and 360‐degree selective laser trabeculoplasty (<scp>SLT</scp>): A 2‐year follow‐up

Tawfique, Kozar; Khademi, Pardis; Quérat, Laurence; Khadamy, Joobin; Chen, Enping

doi:10.1111/aos.13949

Cited by 16 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Once again, higher baseline IOP was the only predictor of treatment success (defined as longer survival time). 68 …”

Section: Resultsmentioning

confidence: 99%

“…Across all of the studies summarized in Table 5 , four reported on the energy range used for treatment, which varied between 0.2 and 1.4 mJ per treatment spot. 11 , 68 , 69 , 70 The mean total energy was reported in two studies as 73.6 and 90.2 mJ. 50 , 71 Another study compared the effectiveness of SLT at 90, 180 or 360 degrees to that of topical treatment, 58 while in the other seven studies the energy was applied to 360 degrees of the TM.…”

Section: Slt Dose Response Versus Topical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review

Radcliffe

Gazzard

Samuelson

et al. 2022

Journal of Glaucoma

View full text Add to dashboard Cite

Précis: A literature review of selective laser trabeculoplasty (SLT) energy dose-response found no definitive relationship between intraocular pressure (IOP) reduction with respect to total or pulse energy, race, pigmentation, or application pattern. Purpose: SLT is a safe and effective treatment for lowering IOP. Although evidence is mounting for the advantage of its use as a first-line treatment for IOP reduction, the SLT procedures in use vary widely. The purpose of this literature review was to investigate whether there were any relationships between SLT energy and efficacy for lowering IOP in the published literature. Methods: A literature review was undertaken that included studies in which energy levels required for successful SLT treatment were investigated: in general, with respect to angle pigmentation, race or ethnicity, and treatment arc extent. Results: There was no indication that higher (or lower) energy used in the treatment leads to greater (or less) IOP reduction. Similar results were obtained regarding the level of trabecular meshwork pigmentation. Race was not found to be associated with altered dose response in SLT. There were indications that treating the full 360 degrees, as opposed to smaller arcs, could be beneficial for more IOP reduction. IOP reduction from SLT was found to be similar to that provided by topical medications. Conclusions: The optimal energy level of SLT needed for IOP reduction has not yet been definitively established, with all reported pulse energies resulting in similar IOP reduction. Furthermore, similar lack of conclusive findings exists regarding optimal SLT energy dosage for use in different races and degrees of trabecular meshwork pigmentation. This parameter and each of the abovementioned factors requires further research.

show abstract

“…Once again, higher baseline IOP was the only predictor of treatment success (defined as longer survival time). 68 …”

Section: Resultsmentioning

confidence: 99%

Section: Slt Dose Response Versus Topical Treatmentmentioning

confidence: 99%

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review

Radcliffe

Gazzard

Samuelson

et al. 2022

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…In the present study, the average amount of laser spots did not differ significantly between the groups that permitted the comparison between the PACG and POAG eyes. Moreover, according to the recent literature, even the 90°SLT is as effective as 360°SLT in a longterm period [30]. e interpretation of the glaucoma progression is rather challenging as many different factors may affect a glaucoma course [31][32][33].…”

Section: Discussionmentioning

confidence: 99%

Selective Laser Trabeculoplasty Protects Glaucoma Progression in the Initial Primary Open-Angle Glaucoma and Angle-Closure Glaucoma after Laser Peripheral Iridotomy in the Long Term

Kurysheva¹,

Lepeshkina

2019

BioMed Research International

View full text Add to dashboard Cite

Purpose. To compare the ability of SLT in preventing glaucoma progression in the initial primary angle-closure glaucoma (PACG) after laser peripheral iridotomy and primary open-angle glaucoma (POAG) in the long term. Methods. 60 patients with the initial stage of PACG after laser peripheral iridotomy and 64 initial POAG patients were recruited in a prospective study. Complete success of selective laser trabeculoplasty (SLT) was defined as a 20% intraocular pressure (IOP) reduction with topical hypotensive medications without any hypotensive intervention. Pre-SLT rate of progression and post-SLT rate of progression (ROP) was detected in the both groups by means of the trend and the event analysis of perimetry, the Guided Progression Analysis, and the optical coherence tomography- (OCT-) based negative trend for either the thickness of the peripapillary retinal nerve fiber layer (RNFL) or ganglion cell complex (GCC). Results. IOP decreased significantly after SLT in both the groups. 30% in PACG and 19% in POAG had the progression according to perimetry and 49% in PACG and 40% in POAG had the progression, respectively, according to OCT. After SLT, ROP was reduced from −0.14 ± 0.39 dB/year to −0.08 ± 0.48 dB/year, p=0.034, in PACG and from −0.09 ± 0.36 dB/year to −0.04 ± 0.43 dB/year, p=0.021, in POAG. According to RNFL trend analysis, ROP was reduced from −1.86 ± 2.9 μm/year to −1.38 ± 2.2 μm/year, p=0.039, and from −1.24 ± 2.23 μm/year to −0.76 ± 1.73 μm/year, p=0.037, in PACG and POAG, and according to GCC, ROP was reduced from −1.88 ± 2.9 μm/year to −1.34 ± 2.0 μm/year, p=0.040, and from −1.35 ± 2.16 μm/year to −0.91 ± 1.86 μm/year, p=0.040, in PACG and POAG, respectively. ROP was significantly faster in PACD than in POAG between 2 and 6 years after SLT: −0.15 ± 0.46 dB/year and 0.02 ± 0.38 dB/year (p=0.042). However, it did not differ significantly according to OCT. Conclusion. SLT is an effective treatment for initial PACG after LPI and POAG that can prevent functional and structural deterioration in the long term.

show abstract

“…In China, medication currently serves as the mainstream first-line treatment for POAG and OHT 14 . Studies in China 15,16 and other countries [17][18][19] have reported greatly varied treatment efficacy for SLT which is possibly due to differences in severity of glaucoma, ethnic background 20,21 , laser energy used, treatment area and length of follow-up. In the past, SLT has been mainly used for cases with uncontrolled IOP, intolerance to medical therapy and poor compliance in mild POAG [46][47][48] .…”

Section: Introductionmentioning

confidence: 99%

Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China – A Randomized Controlled Trial: Design and Baseline Characteristics

Yang

Jiang

Sheng

et al. 2021

American Journal of Ophthalmology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Comparison between 90‐degree and 360‐degree selective laser trabeculoplasty (SLT): A 2‐year follow‐up

Cited by 16 publications

References 16 publications

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review

Selective Laser Trabeculoplasty Protects Glaucoma Progression in the Initial Primary Open-Angle Glaucoma and Angle-Closure Glaucoma after Laser Peripheral Iridotomy in the Long Term

Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China – A Randomized Controlled Trial: Design and Baseline Characteristics

Contact Info

Product

Resources

About